HeartPort: Still Beating
Executive Summary
Once one of the highest-flying medical device companies of the 1990s, the last couple of years have not been easy for minimally-invasive cardiac surgery company, HeartPort Inc. The company developed an innovative approach to minimally-invasive bypass and heart valve surgery, one that incorporated the use of CPB (coronary-pulmonary bypass) in a closed procedure on the theory that CPB is the gold standard in open procedures. The problem is, no one wanted it. (Most surgeons would like to eliminate CPB from open procedures, if possible.) As adoption rates of its technology lagged far behind the company's projections, HeartPort became a fading star. But company officials insist HeartPort's fortunes are turning around.
You may also be interested in...
HeartFlow: Disrupting The Diagnostic Paradigm In Cardiology
Most current cardiac diagnostic imaging tests are highly inexact, relying heavily on clinicians' observations. HeartFlow is adapting advanced computer modeling to cardiology to produce a precise, predictive, noninvasive diagnostic that doubles as a treatment planning tool. The test could eliminate unnecessary procedures for patients and save the system money, but is that what interventionalists want?
HeartFlow: Disrupting The Diagnostic Paradigm In Cardiology
Most current cardiac diagnostic imaging tests are highly inexact, relying heavily on clinicians' observations. HeartFlow is adapting advanced computer modeling to cardiology to produce a precise, predictive, noninvasive diagnostic that doubles as a treatment planning tool. The test could eliminate unnecessary procedures for patients and save the system money, but is that what interventionalists want?
Cardica: Rebuilding the Cardiac Surgery Market
The predicted expansion of beating-heart and minimally-invasive cardiac surgery never materialized, a result, some say, of the lack of safe and effective automated anastomotic tools. Cardica believes it has the answer that can at long last grow this market.